LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Charles River Laboratories International Inc

Închisă

SectorSănătate

179.88 -1.68

Rezumat

Modificarea prețului

24h

Curent

Minim

181.52

Maxim

185.77

Indicatori cheie

By Trading Economics

Venit

2.9M

56M

Vânzări

-27M

1B

P/E

Medie Sector

592.3

80.03

EPS

2.43

Marjă de profit

5.529

Angajați

18,700

EBITDA

-23M

198M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+10.28% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-136M

8.7B

Deschiderea anterioară

181.56

Închiderea anterioară

179.88

Sentimentul știrilor

By Acuity

15%

85%

20 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Charles River Laboratories International Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 dec. 2025, 23:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec. 2025, 23:14 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec. 2025, 22:01 UTC

Principalele dinamici ale pieței

Costco Wholesale Reports Higher Monthly Sales

3 dec. 2025, 21:38 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec. 2025, 23:10 UTC

Câștiguri

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec. 2025, 23:06 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec. 2025, 22:20 UTC

Câștiguri

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec. 2025, 22:19 UTC

Câștiguri

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec. 2025, 22:17 UTC

Câștiguri

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec. 2025, 22:16 UTC

Câștiguri

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec. 2025, 22:15 UTC

Câștiguri

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec. 2025, 22:09 UTC

Achiziții, Fuziuni, Preluări

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 dec. 2025, 21:49 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:23 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec. 2025, 21:19 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:06 UTC

Câștiguri

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec. 2025, 21:03 UTC

Câștiguri

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparație

Modificare preț

Charles River Laboratories International Inc Așteptări

Obiectiv de preț

By TipRanks

10.28% sus

Prognoză pe 12 luni

Medie 192.73 USD  10.28%

Maxim 225 USD

Minim 165 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCharles River Laboratories International Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

7

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

117.16 / 144.77Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

20 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat